Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coherus OncologyFRA:8C5 +0.81%49 Cyclically Adjusted PS Ratio is 0.43 as of Jul. 26, 2026, which is 7% below its 10-year median of 0.46. GuruFocus rates FRA:8C5 with a GF Score™ of 49/100 and a GF Value™ of €0.65 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 538 Biotechnology companies, Coherus Oncology ranks better than 90.71% on this metric.
The historical rank and industry rank for Coherus Oncology's Cyclically Adjusted PS Ratio or its related term are showing as below:
FRA:8C5'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.21 Med: 0.46 Max: 2.48
Current: 0.4
During the past years, Coherus Oncology's highest Cyclically Adjusted PS Ratio was 2.48. The lowest was 0.21. And the median was 0.46.
FRA:8C5's Cyclically Adjusted PS Ratio is ranked better than 90.71% of 538
companies
in the Biotechnology industry
Industry Median: 5.585
vs FRA:8C5: 0.40
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Coherus Oncology's adjusted revenue per share data for the three months ended in Mar. 2026 was €0.078. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.91 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Coherus Oncology (FRA:8C5) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Coherus Oncology Cyclically Adjusted PS Ratio Related Terms
Coherus Oncology Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology Cyclically Adjusted PS Ratio Chart
FRA:8C5 vs TARA, KPTI, CNTN: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Coherus Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Cyclically Adjusted PS Ratio falls into.
Coherus Oncology Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Coherus Oncology's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.43 mean?
Coherus Oncology (FRA:8C5) has a Cyclically Adjusted PS Ratio of 0.43 as of Jul. 26, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Coherus Oncology and its competitors. This is near median its historical median of 0.46. Over the past decade, Coherus Oncology's Cyclically Adjusted PS Ratio has ranged from 0.21 to 2.48. According to the industry distribution chart, Coherus Oncology ranks #50 out of 538 companies in the Biotechnology industry, placing it in the top 9.3%.
Is Coherus Oncology's Cyclically Adjusted PS Ratio too high?
Coherus Oncology's current Cyclically Adjusted PS Ratio of 0.43 is near median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 2.48. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.59. Coherus Oncology's value of 0.43 is 92.3% below this industry median. Based on the distribution chart, Coherus Oncology ranks #50 out of 538 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coherus Oncology has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Cyclically Adjusted PS Ratio compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #50 out of 538 companies for Cyclically Adjusted PS Ratio. This places Coherus Oncology in the top 9% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PS Ratio is 5.59. Coherus Oncology's value of 0.43 is 92.3% below this benchmark. Historically, Coherus Oncology's own Cyclically Adjusted PS Ratio has ranged from 0.21 to 2.48 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 5.59, Coherus Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.59, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Cyclically Adjusted PS Ratio of 0.43 is 92.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Cyclically Adjusted PS Ratio is 0.43, which is near median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €1.24 — trading 90.3% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.43, which is near median its 10-year median of 0.46 and 92.3% below the Biotechnology industry median of 5.59. Coherus Oncology's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Cyclically Adjusted PS Ratio is 0.43 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.24 is trading 90.3% above its estimated GF Value™ of €0.65.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
Cyclically Adjusted PS Ratio: 0.43 (near median its 10-year median of 0.46)
GF Value™: €0.65 vs. price of €1.24 (90.3% above fair value)
Industry Position: 92.3% below the Biotechnology median (#50 of 538)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
49GF Score
Get the complete analysis for FRA:8C5
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
